HUP0103883A2 - Új, késleltetett felszabadulású, orális készítmények - Google Patents

Új, késleltetett felszabadulású, orális készítmények

Info

Publication number
HUP0103883A2
HUP0103883A2 HU0103883A HUP0103883A HUP0103883A2 HU P0103883 A2 HUP0103883 A2 HU P0103883A2 HU 0103883 A HU0103883 A HU 0103883A HU P0103883 A HUP0103883 A HU P0103883A HU P0103883 A2 HUP0103883 A2 HU P0103883A2
Authority
HU
Hungary
Prior art keywords
water
component
active substance
sustained release
oral formulations
Prior art date
Application number
HU0103883A
Other languages
English (en)
Inventor
Oskar Kalb
Satish Chandra Khanna
Jörg Ogorka
Rajen Shah
Original Assignee
Novartis Ag.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27547321&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0103883(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9821299.6A external-priority patent/GB9821299D0/en
Priority claimed from GBGB9821298.8A external-priority patent/GB9821298D0/en
Priority claimed from GBGB9826654.7A external-priority patent/GB9826654D0/en
Priority claimed from GBGB9827624.9A external-priority patent/GB9827624D0/en
Priority claimed from GBGB9907822.2A external-priority patent/GB9907822D0/en
Priority claimed from GBGB9907823.0A external-priority patent/GB9907823D0/en
Application filed by Novartis Ag. filed Critical Novartis Ag.
Publication of HUP0103883A2 publication Critical patent/HUP0103883A2/hu
Publication of HUP0103883A3 publication Critical patent/HUP0103883A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

A találmány tárgya egy orális gyógyszerkészítmény, amely a hatóanyagotaz időben szabályozott módon adja le. A készítményben van egy elsőkomponens, amely tartalmaz egy első hatóanyagdózist, amelynek 70-95 %-át vízzel érintkezve 3-4 órán belül leadja és egy második komponens,amely tartalmaz egy második hatóanyagdózist, egy vízoldhatóozmotizálószert és egy vízben duzzadó kötőanyagot, ennek a másodikkomponensnek van egy vízáteresztő bevonata, amely az alkalmazás sorána vízzel érintkezve bizonyos késleltetési idő után felhasad, és ahatóanyagot kibocsátja. A találmány szerinti gyógyszerkészítményenyhén-közepesen súlyos Alzheimer-féle dementiában szenvedő betegekkezelésére alkalmazható. Ó
HU0103883A 1998-10-01 1999-10-01 New sustained release oral formulations HUP0103883A3 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GBGB9821299.6A GB9821299D0 (en) 1998-10-01 1998-10-01 Organic compounds
GBGB9821298.8A GB9821298D0 (en) 1998-10-01 1998-10-01 Organic compoundsq
GBGB9826654.7A GB9826654D0 (en) 1998-12-03 1998-12-03 Organic compounds
GBGB9827624.9A GB9827624D0 (en) 1998-12-16 1998-12-16 Organic compounds
GBGB9907822.2A GB9907822D0 (en) 1999-04-06 1999-04-06 Organic compounds
GBGB9907823.0A GB9907823D0 (en) 1999-04-06 1999-04-06 Organic compounds

Publications (2)

Publication Number Publication Date
HUP0103883A2 true HUP0103883A2 (hu) 2002-05-29
HUP0103883A3 HUP0103883A3 (en) 2002-11-28

Family

ID=27547321

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0103883A HUP0103883A3 (en) 1998-10-01 1999-10-01 New sustained release oral formulations

Country Status (23)

Country Link
US (5) US20010033866A1 (hu)
EP (1) EP1121104B1 (hu)
JP (1) JP4012689B2 (hu)
KR (1) KR100603900B1 (hu)
CN (1) CN1406126A (hu)
AT (1) ATE286725T1 (hu)
AU (1) AU764866B2 (hu)
BR (1) BR9914251A (hu)
CA (1) CA2342340C (hu)
CZ (1) CZ302888B6 (hu)
DE (1) DE69923200T2 (hu)
ES (1) ES2237163T3 (hu)
HK (1) HK1052473A1 (hu)
HU (1) HUP0103883A3 (hu)
ID (1) ID27504A (hu)
IL (2) IL141762A0 (hu)
NO (1) NO331689B1 (hu)
NZ (1) NZ510683A (hu)
PL (1) PL196945B1 (hu)
PT (1) PT1121104E (hu)
SK (1) SK285250B6 (hu)
TR (1) TR200100931T2 (hu)
WO (1) WO2000019985A2 (hu)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9914251A (pt) * 1998-10-01 2001-06-19 Novartis Ag Formulações orais de liberação sustentada
EP1133230A4 (en) * 1998-11-23 2004-05-26 Bonnie M Davis DOSAGE FORMULAS FOR ACETYLCHOLINESTERASE INHIBITORS
CA2380333A1 (en) * 1999-08-26 2001-03-01 Christian Andina Pharmaceutical formulations
GB9923045D0 (en) * 1999-09-29 1999-12-01 Novartis Ag New oral formulations
AU2357202A (en) * 2000-09-29 2002-04-08 Solvay Pharm Bv Ion-strength independent sustained release pharmaceutical formulation
JP5023412B2 (ja) * 2001-05-09 2012-09-12 吉澤石灰工業株式会社 ホルムアルデヒド廃液の処理剤
DE60223695T2 (de) * 2001-09-14 2008-10-30 Scolr, Inc., Redmond Aminosäure-modulierte dosierform mit verlängerter freisetzung
JP2005525299A (ja) * 2001-09-14 2005-08-25 スコラー インコーポレイテッド アミノ酸調節性の長期放出投薬形態
KR100453288B1 (ko) * 2002-03-12 2004-10-21 한국화학연구원 약물의 제어 방출을 위한 스퀴즈-유형의 삼투성 약물 전달장치
PT1529116E (pt) * 2002-08-07 2009-09-10 Novartis Ag Métodos para o tratamento da demência com base no genótipo da apo e
ZA200508653B (en) * 2003-04-07 2007-03-28 Jurox Pty Ltd Stable carprofen composition
US8158149B2 (en) * 2004-05-12 2012-04-17 Chelsea Therapeutics, Inc. Threo-DOPS controlled release formulation
US20060105036A1 (en) * 2003-05-12 2006-05-18 Stephen Peroutka Threo-dops controlled release formulation
MEP3608A (en) * 2003-08-08 2011-05-10 Biovail Lab Int Srl Modified-release tablet of bupropion hydrochloride
US20100129310A1 (en) * 2004-08-09 2010-05-27 Pavak Rajnikanth Mehta Stabilized desloratadine composition
ES2403069T3 (es) * 2005-02-22 2013-05-13 Sun Pharma Advanced Research Company Ltd Composición oral de liberación controlada que contiene levetiracetam
CA2606740A1 (en) * 2005-05-03 2006-11-09 Mutual Pharmaceutical Company, Inc. Quinine-containing controlled-release formulations
CA2620594C (en) * 2005-09-01 2012-08-21 Eisai R&D Management Co., Ltd. Pharmaceutical composition having improved disintegratability
GB0525461D0 (en) 2005-12-15 2006-01-25 Archimedes Dev Ltd Pharmaceutical compositions
GB0606562D0 (en) * 2006-03-31 2006-05-10 Novartis Ag Organic compounds
US7803778B2 (en) 2006-05-23 2010-09-28 Theracos, Inc. Glucose transport inhibitors and methods of use
US7893053B2 (en) 2006-06-16 2011-02-22 Theracos, Inc. Treating psychological conditions using muscarinic receptor M1 antagonists
US8748419B2 (en) 2006-06-16 2014-06-10 Theracos, Inc. Treating obesity with muscarinic receptor M1 antagonists
BRPI0809607A2 (pt) 2007-04-02 2014-09-30 Theracos Inc Composto, composição farmacêutica, combinação farmacêutica, e, método para tratar uma doença
ITMI20071502A1 (it) * 2007-07-25 2009-01-26 Archimica Srl Procedimento per la preparazione di formulazioni solide a rilascio controllato contenenti oxcarbazepina e formulazioni ottenibili con tale procedimento
WO2009022345A1 (en) * 2007-08-14 2009-02-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem Phenyl carbamates for the treatment of multiple sclerosis
BRPI0815708B8 (pt) 2007-08-23 2021-05-25 Theracos Sub Llc composto, éster de pró-droga, composição farmacêutica, e, método para tratar uma doença ou condição
US20100204303A1 (en) * 2007-09-25 2010-08-12 Idexx Laboratories, Inc. Pharmaceutical Compositions for Administering Oligonucleotides
US20110201597A1 (en) 2008-03-27 2011-08-18 Chase Thomas N Method and composition for treating alzheimer-type dementia
FR2931677B1 (fr) * 2008-06-02 2010-08-20 Sanofi Aventis Association d'un agoniste partiel des recepteurs nicotiniques et d'un inhibiteur d'acetylcholinesterase, composition la contenant et son utilisation dans le traitement des troubles cognitifs
US9061060B2 (en) 2008-07-15 2015-06-23 Theracos Inc. Deuterated benzylbenzene derivatives and methods of use
KR101654231B1 (ko) 2008-08-22 2016-09-05 테라코스 서브, 엘엘씨 Ｓｇｌｔ２ 억제제의 제조방법
CN102264743B (zh) 2008-11-25 2015-02-11 罗彻斯特大学 Mlk抑制剂及其使用方法
AU2010296044B2 (en) * 2009-09-18 2015-05-14 Chase Pharmaceuticals Corporation Method and composition for treating Alzheimer-type dementia
US20110150986A1 (en) * 2009-12-18 2011-06-23 Kristin Arnold Quinine formulations, method of making, and metho of use thereof
CN101797236B (zh) * 2010-03-23 2012-05-23 西南大学 重酒石酸卡巴拉汀口腔崩解片及其制备方法
JP6086326B2 (ja) 2010-05-24 2017-03-01 ユニヴァーシティー オブ ロチェスター 二環式ヘテロアリールキナーゼ阻害剤および使用方法
WO2011151359A1 (en) 2010-06-02 2011-12-08 Noscira, S.A. Combined treatment with a cholinesterase inhibitor and a thiadiazolidinedione derivative
WO2011153712A1 (en) 2010-06-12 2011-12-15 Theracos, Inc. Crystalline form of benzylbenzene sglt2 inhibitor
EP3502236B1 (en) 2011-02-18 2023-08-23 The Scripps Research Institute Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate
WO2012144463A1 (ja) 2011-04-18 2012-10-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療剤
TW201306881A (zh) * 2011-05-06 2013-02-16 Glaxosmithkline Llc 緩釋對乙醯胺基酚調配物
BR112013029199B1 (pt) * 2011-05-13 2022-02-08 Eb Ip Hybritabs B.V. Dispositivo de distribuição de dois fármacos
US8524664B2 (en) 2011-06-02 2013-09-03 Colorado Seminary, Which owns and Operates The Univeristy of Denver Methods of treating overproduction of cortisol using ACTH antagonist peptides
US9945862B2 (en) 2011-06-03 2018-04-17 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
JP6285865B2 (ja) 2011-11-14 2018-02-28 アルファシグマ ソシエタ ペル アチオニ うつ病を有する対象のための処置レジメンを選択するためのアッセイ及び方法
KR20150048888A (ko) 2012-09-05 2015-05-07 체이스 파마슈티칼스 코포레이션 항콜린 신경보호 조성물 및 그 방법
WO2014085795A1 (en) 2012-11-30 2014-06-05 University Of Rochester Mixed lineage kinase inhibitors for hiv/aids therapies
CN104755463A (zh) 2012-12-21 2015-07-01 卫材R&D管理有限公司 非晶态形式的喹啉衍生物及其生产方法
US10517861B2 (en) 2013-05-14 2019-12-31 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
ES2888074T3 (es) 2013-08-16 2021-12-30 Univ Maastricht Tratamiento del deterioro cognitivo con inhibidor de PDE4
WO2015136446A1 (en) 2014-03-11 2015-09-17 Nestec S.A. Methods for selecting antidepressant drug therapy to treat depression
CN103877063A (zh) * 2014-03-24 2014-06-25 张绪伟 一种重酒石酸卡巴拉汀胶囊及其制备方法
ES2926687T3 (es) 2014-08-28 2022-10-27 Eisai R&D Man Co Ltd Derivado de quinolina muy puro y método para su producción
PL3263106T3 (pl) 2015-02-25 2024-04-02 Eisai R&D Management Co., Ltd. Sposób tłumienia goryczy pochodnej chinoliny
WO2016140717A1 (en) 2015-03-04 2016-09-09 Merck Sharp & Dohme Corp. Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
KR101990951B1 (ko) * 2015-04-27 2019-06-20 주식회사 네비팜 리바스티그민 함유 서방출 의약조성물
ES2886107T3 (es) 2015-06-16 2021-12-16 Prism Biolab Co Ltd Antineoplásico
IL243707A0 (en) 2016-01-20 2016-05-01 Galmed Res And Dev Ltd Treatment to regulate the microbiota in the intestine
KR20190021180A (ko) * 2017-08-22 2019-03-05 아주대학교산학협력단 퇴행성 신경질환 치료용 복합 제형 조성물
KR20190036370A (ko) 2017-09-27 2019-04-04 서원대학교산학협력단 약물의 서방성 제형을 위한 약물전달체
HRP20240162T1 (hr) 2018-07-30 2024-04-12 Biothea Pharma, Inc. Kristalna sol epinefrin malonata
CN112546037A (zh) * 2020-12-08 2021-03-26 苏州大学 卡巴拉汀在制备抗辐射药中的应用
CN113398273B (zh) * 2021-05-14 2022-07-19 广西壮族自治区中国科学院广西植物研究所 木聚糖衍生物作为亲水性缓释材料在制备药物缓释片中的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4014335A (en) * 1975-04-21 1977-03-29 Alza Corporation Ocular drug delivery device
USRE34990E (en) * 1986-08-07 1995-07-04 Ciba-Geigy Corporation Oral therapeutic system having systemic action
DE3805744C2 (de) * 1987-03-04 1999-09-23 Novartis Ag Phenylcarbamate zur Hemmung der Acetylcholinesterase
HU201906B (en) 1987-03-04 1991-01-28 Sandoz Ag Process for producing phenyl-carbamate derivative and acid additional salts and pharmaceutical compositions containing them
DE3922167A1 (de) * 1988-04-16 1991-01-17 Sanol Arznei Schwarz Gmbh Oral zu verabreichende diltiazemhydrochlorid enthaltende pharmazeutische zubereitung zur einmal taeglichen applikation und verfahren zu deren herstellung
US5472710A (en) * 1988-04-16 1995-12-05 Schwarz Pharma Ag Pharmaceutical preparation to be administered orally with controlled release of active substance and method for its manufacture
US5262173A (en) * 1992-03-02 1993-11-16 American Cyanamid Company Pulsatile once-a-day delivery systems for minocycline
US5260068A (en) * 1992-05-04 1993-11-09 Anda Sr Pharmaceuticals Inc. Multiparticulate pulsatile drug delivery system
EP0621032B1 (en) * 1993-04-23 2000-08-09 Novartis AG Controlled release drug delivery device
US5698224A (en) * 1994-06-27 1997-12-16 Alza Corporation Tacrine therapy
US5962535A (en) * 1997-01-17 1999-10-05 Takeda Chemical Industries, Ltd. Composition for alzheimer's disease
GB9701695D0 (en) 1997-01-28 1997-03-19 De Beers Ind Diamond Insert for an abrasive tool
DE19707655A1 (de) * 1997-02-26 1998-08-27 Hoechst Ag Kombinationspräparat zur Anwendung bei Demenz
ATE250929T1 (de) * 1997-05-30 2003-10-15 Osmotica Corp Mehrlagige osmosevorrichtung
GB9800526D0 (en) * 1998-01-12 1998-03-11 Ciba Geigy Ag Organic compounds
BR9914251A (pt) * 1998-10-01 2001-06-19 Novartis Ag Formulações orais de liberação sustentada
US6534541B1 (en) 1999-10-19 2003-03-18 Novartis Ag Treatment of ocular disorders

Also Published As

Publication number Publication date
WO2000019985A3 (en) 2000-07-20
NO20011471L (no) 2001-03-22
NO20011471D0 (no) 2001-03-22
SK285250B6 (sk) 2006-09-07
US20030039692A1 (en) 2003-02-27
DE69923200D1 (de) 2005-02-17
NZ510683A (en) 2003-09-26
NO331689B1 (no) 2012-02-27
US20070053982A1 (en) 2007-03-08
US20010033866A1 (en) 2001-10-25
ID27504A (id) 2001-04-12
SK4392001A3 (en) 2002-07-02
PL196945B1 (pl) 2008-02-29
PL348734A1 (en) 2002-06-03
BR9914251A (pt) 2001-06-19
WO2000019985A2 (en) 2000-04-13
KR20010073168A (ko) 2001-07-31
US6565883B2 (en) 2003-05-20
IL141762A (en) 2010-06-30
JP2002526402A (ja) 2002-08-20
IL141762A0 (en) 2002-03-10
CA2342340A1 (en) 2000-04-13
CA2342340C (en) 2006-08-29
AU6332199A (en) 2000-04-26
KR100603900B1 (ko) 2006-07-25
CZ302888B6 (cs) 2012-01-11
JP4012689B2 (ja) 2007-11-21
EP1121104A2 (en) 2001-08-08
US20050175706A1 (en) 2005-08-11
CN1406126A (zh) 2003-03-26
AU764866B2 (en) 2003-09-04
EP1121104B1 (en) 2005-01-12
ES2237163T3 (es) 2005-07-16
US20030203025A1 (en) 2003-10-30
TR200100931T2 (tr) 2001-10-22
DE69923200T2 (de) 2005-12-22
HK1052473A1 (zh) 2003-09-19
CZ20011155A3 (cs) 2001-08-15
ATE286725T1 (de) 2005-01-15
HUP0103883A3 (en) 2002-11-28
PT1121104E (pt) 2005-05-31

Similar Documents

Publication Publication Date Title
HUP0103883A2 (hu) Új, késleltetett felszabadulású, orális készítmények
DK1115384T3 (da) Fentanyl-præparat til behandling af akutte smerter
ATE211385T1 (de) Anwendungsformen zur behandlung der männlichen erektilen dysfunktion
HUP0301400A2 (hu) Gyógyszerösszetétel és adagolási forma az alendronát és/vagy más biszfoszfonátoknak a gyomorban történż késleltetett felszabadulására
HK1046244A1 (en) Controlled release and taste masking oral pharmaceutical compositions.
HUP0401714A2 (hu) Propiverin vagy gyógyászatilag elfogadható sóinak nyújtott hatóanyag-eladású, orális adagolási formái
AP1748A (en) Chronotherapeutic dosage forms.
IS2156B (is) Settar bensensúlfonamíðafleiður sem forlyf fyrir COX-2 tálma, aðferð til þess að búa þær til, lyfjasamsetningar sem innihalda þær og notkun þeirra við framleiðslu lyfja
RS56252B1 (sr) Jednodnevne formulacije oksikodona
HUP0301591A2 (hu) Szabályozott hatóanyag-leadású hidrokodon-készítmények
DK0949925T3 (da) Flad lægemiddelform til anbringelse i mundhulen med frigivelse der af buprenorphin eller et farmakologisk sammenligneligt stof, samt fremgangsmåde til fremstilling deraf
TR199903280T2 (xx) Sertralin tuzlar� ve sertralinin tutmal�-bo�altma dozaj bi�imleri.
ATE345782T1 (de) Dosierungsformen enthaltend geschmacksmaskierten wirkstoffen
ATE302588T1 (de) Dentales produkt gegen zahnstein und betreffende methode
HUP0102206A2 (hu) Delavirdint tartalmazó tabletta formájú készítmény
HUP9901794A2 (hu) Protonpumpa inhibitorok új beadási formája
SE0300831D0 (sv) New formulations and use therof
HUP9801227A2 (hu) Monoamin-oxidáz B inhibitorokból álló gyógyászati készítmények és alkalmazásuk
HUP0103454A2 (hu) Entacapont vagy nitecapont és keresztkötésű cellulózszármazékot tartalmazó gyógyászati készítmény
HUP0401308A2 (hu) Folyékony polimer kompozíció szájüregi betegségek megelőzésére és kezelésére
DK1345595T3 (da) Ionstyrke-uafhængig farmaceutisk formulering med depotfrigivelse
RS49599B (sr) Upotreba inhibitora h+, k+-atp-aze i glukokortikoida i farmaceutska formulacija
HUP0001104A2 (hu) Ibuprofent és domperidont tartalmazó készítmények migrén kezelésére
HUP0204417A2 (en) Oral ciprofloxacin-composition of controlled release
WO2002096870A3 (en) Sponge-derived terpenoids and methods of use

Legal Events

Date Code Title Description
FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished